Sign inJoin waitlistJoin the waitlist

Ricklie Julian

Associate Professor, Medicine - · University of Arizona College of Medicine-Tucson

Credentials: · · · · · ·

History

University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present

Hematology and Medical Oncology
NYU Grossman School of Medicine
2016–2019
Albert Einstein College of Medicine of Yeshiva University
2013–2016
George Washington University Medical School
2009–2013
University of Florida
2005–2009

Research

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Cancer Discovery · 2024 · 86 citations
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
Journal of Clinical Oncology · 2023 · 50 citations
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
Review · Journal of Thoracic Oncology · 2019 · 46 citations

Julie Bauman
5 papers
Nabil Saba
3 papers
Audrey Baker
2 papers
Jessica Bauman
2 papers
John Kaczmar
2 papers
Shethal Bearelly
2 papers
Steven Wang
2 papers
Aaron Scott
1 paper
Aarti Bhatia
1 paper
AH
Alan Ho
1 paper
AP
Andrew Poklepovic
1 paper
Anshu Giri
1 paper

Clinical trials

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
Principal investigator · Terminated · Phase 2
University of Arizona
2021–2025
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
Principal investigator · Terminated · Phase 2
University of Arizona
2019–2022
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Study chair · Recruiting · Phase 1, Phase 2
University of Arizona
2025–2030
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Site PI · Not yet recruiting · Phase 3
Corbus Pharmaceuticals Inc.
2026–2029